Tier 2 — strong

Bioavailability of US commercial magnesium preparations

M Firoz, M Graber
Magnesium research 2001 14(4):257-62

Bibliography

PubMed
PMID 11794633
Funding
Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignComparative human bioavailability study
ModelHuman participants
SampleHealthy volunteers; sample size not stated in the indexed abstract
InterventionApproximately 21 mEq/day magnesium from oxide, chloride, lactate or aspartate preparations
DurationShort-term bioavailability assessment
EndpointsIncremental urinary magnesium excretion

What the study showed, in plain terms

This publication examines incremental urinary magnesium excretion. Study population or evidence base: Healthy volunteers; sample size not stated in the indexed abstract. Intervention or exposure: Approximately 21 mEq/day magnesium from oxide, chloride, lactate or aspartate preparations.

Key findings

Oxide showed lower absorption than the chloride, lactate and aspartate preparations tested. The findings illustrate that elemental content and formulation both matter.

What this study can and cannot tell us

Urinary excretion is a bioavailability proxy. The study does not compare every magnesium salt or demonstrate clinical benefits from a particular preparation.

Related papers in the corpus

Tier 2
Magnesium bioavailability from magnesium citrate and magnesium oxide
J S Lindberg et al. · Journal of the American College of Nutrition · 1990
Tier 2
Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans
V V Ranade et al. · American journal of therapeutics · 2001
Tier 2
Assessment of bioavailability of Mg from Mg citrate and Mg oxide by measuring urinary excretion in Mg-saturated subjects
Tanja Werner et al. · Magnesium research · 2019
Tier 1
Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPETM Microcapsules) Versus Other Magnesium Sources
David Pajuelo et al. · Nutrients · 2024
Tier 2
Magnesium bioavailability after administration of sucrosomial® magnesium: results of an ex-vivo study and a comparative, double-blinded, cross-over study in healthy subjects
E Brilli et al. · European review for medical and pharmacological sciences · 2018
Tier 2
Comparing the Bioavailability of Two Seawater-Derived Magnesium Preparations
Brian K McFarlin et al. · Journal of medicinal food · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research